These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34427495)

  • 1. Intrathecal Transplantation of Autologous and Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Dogs.
    Benavides FP; Pinto GBA; Heckler MCT; Hurtado DMR; Teixeira LR; Monobe MMS; Machado GF; de Melo GD; Rodríguez-Sánchez DN; Alvarenga FDCLE; Amorim RM
    Cell Transplant; 2021; 30():9636897211034464. PubMed ID: 34427495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-bladder wall transplantation of bone marrow mesenchymal stem cells improved urinary bladder dysfunction following spinal cord injury.
    Salehi-Pourmehr H; Rahbarghazi R; Mahmoudi J; Roshangar L; Chapple CR; Hajebrahimi S; Abolhasanpour N; Azghani MR
    Life Sci; 2019 Mar; 221():20-28. PubMed ID: 30735734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.
    Barberini DJ; Aleman M; Aristizabal F; Spriet M; Clark KC; Walker NJ; Galuppo LD; Amorim RM; Woolard KD; Borjesson DL
    Stem Cell Res Ther; 2018 Apr; 9(1):96. PubMed ID: 29631634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation.
    Luo XY; Kong Y; Lv M; Mo XD; Wang Y; Xu LP; Zhang XH; Huang XJ; Tang FF
    Br J Haematol; 2023 Mar; 200(6):759-768. PubMed ID: 36464324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and safety of intrathecal transplantation of autologous bone marrow mesenchymal stem cells in horses.
    Maia L; da Cruz Landim-Alvarenga F; Taffarel MO; de Moraes CN; Machado GF; Melo GD; Amorim RM
    BMC Vet Res; 2015 Mar; 11():63. PubMed ID: 25879519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study.
    Wei Y; Chen X; Zhang H; Su Q; Peng Y; Fu Q; Li J; Gao Y; Li X; Yang S; Ye Q; Huang H; Deng R; Li G; Xu B; Wu C; Wang J; Zhang X; Su X; Liu L; Xiang AP; Wang C
    Front Immunol; 2021; 12():662441. PubMed ID: 34248942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.
    Gorodetsky R; Aicher WK
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings.
    Zeira O; Asiag N; Aralla M; Ghezzi E; Pettinari L; Martinelli L; Zahirpour D; Dumas MP; Lupi D; Scaccia S; Konar M; Cantile C
    J Neuroinflammation; 2015 Sep; 12():181. PubMed ID: 26415563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury.
    Jung DI; Ha J; Kang BT; Kim JW; Quan FS; Lee JH; Woo EJ; Park HM
    J Neurol Sci; 2009 Oct; 285(1-2):67-77. PubMed ID: 19555980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.
    Schweizer MT; Wang H; Bivalacqua TJ; Partin AW; Lim SJ; Chapman C; Abdallah R; Levy O; Bhowmick NA; Karp JM; De Marzo A; Isaacs JT; Brennen WN; Denmeade SR
    Stem Cells Transl Med; 2019 May; 8(5):441-449. PubMed ID: 30735000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
    Harris VK; Vyshkina T; Sadiq SA
    Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody.
    Liew A; Baustian C; Thomas D; Vaughan E; Sanz-Nogués C; Creane M; Chen X; Alagesan S; Owens P; Horan J; Dockery P; Griffin MD; Duffy A; O'Brien T
    Cell Transplant; 2018 Aug; 27(8):1210-1221. PubMed ID: 30016879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral nerve regeneration: A comparative study of the effects of autologous bone marrow-derived mesenchymal stem cells, platelet-rich plasma, and lateral saphenous vein graft as a conduit in a dog model.
    Daradka MH; Bani Ismail ZA; Irsheid MA
    Open Vet J; 2021; 11(4):686-694. PubMed ID: 35070865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation: is it clinically relevant?
    Miura Y; Yoshioka S; Yao H; Takaori-Kondo A; Maekawa T; Ichinohe T
    Chimerism; 2013; 4(3):78-83. PubMed ID: 23880502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury: safety considerations and possible outcomes.
    Oraee-Yazdani S; Akhlaghpasand M; Golmohammadi M; Hafizi M; Zomorrod MS; Kabir NM; Oraee-Yazdani M; Ashrafi F; Zali A; Soleimani M
    Stem Cell Res Ther; 2021 Aug; 12(1):445. PubMed ID: 34372939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
    Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
    Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model.
    Mäkelä T; Takalo R; Arvola O; Haapanen H; Yannopoulos F; Blanco R; Ahvenjärvi L; Kiviluoma K; Kerkelä E; Nystedt J; Juvonen T; Lehenkari P
    Cytotherapy; 2015 Apr; 17(4):392-402. PubMed ID: 25601140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of intra-bone marrow infusion of allogeneic mesenchymal stem cells on reconstruction of marrow mesenchymal stem cells in rat HSCT models].
    Cai Y; Huang SL; Chen HQ; Huang YL; Huang K; Zhang XC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1334-8. PubMed ID: 19099639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Autologous Bone Marrow-Derived CD271
    Milczarek O; Jarocha D; Starowicz-Filip A; Kwiatkowski S; Badyra B; Majka M
    Stem Cells Transl Med; 2018 Jan; 7(1):20-33. PubMed ID: 29224250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous.
    Chen JM; Huang QY; Zhao YX; Chen WH; Lin S; Shi QY
    Front Immunol; 2021; 12():785717. PubMed ID: 34868069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.